Printer Friendly

VITAL HEART SYSTEMS, INC. ANNOUNCES FINANCING AND FOURTH QUARTER RESULTS

 BOSTON/MINNEAPOLIS, April 20 /PRNewswire/ -- Vital Heart Systems, Inc. (NASDAQ: VHRT) announced today that it is working with certain investors to complete a private equity financing of up to $1.5 million by the end of April. DaVinci Scientific, Inc. (formerly Varitec Medical, Inc.) is the company's principal distributor and has provided the company with a Letter of Intent to invest $500,000 with some conditions, one of which is that at least an additional $500,000 is raised from other investors. The proceeds raised from the financing will be used in part to reduce current liabilities and to meet the company's near-term operational needs with a focus on sales and marketing.
 "We are pleased with the interest many investors continue to show for Vital Heart Systems and are particularly pleased to receive the financial endorsement from our primary distributor," said John F. Thero, chief financial officer and interim president and chief executive officer. "The proceeds from this financing should allow Vital Heart Systems to further the commercial introduction of the Variance Cardiograph(TM)."
 Vital Heart Systems, Inc., also announced today its fourth quarter and year-end financial results. Revenue recognized in the fourth quarter ended Dec. 31, 1992 totalled $110,721 bringing revenues for the year then ended to $374,144. This compares to revenues for the fourth quarter of 1991 of $6,597 and the year ended Dec. 31, 1991 of $73,650.
 The company recorded a net loss in the fourth quarter of 1992 of $2,129,922, or $.10 per share and a net loss of $3,842,171, or a loss of $.19 per share for thloss for the year ended 1991 of $1,728,593, or $.10 per sha re. Included in the loss for the fourth quarter of 1992 were charges for restructuring totalling $753,262 which primarily reflects the closing of a regional office, reduction in employees and the write-down of certain assets.
 Thero stated, "Our full year loss increased substantially due to increases in sales, marketing and product development costs, in addition to one-time charges of $753,262. Much of the expense incurred in 1992 was for non-recurring items and the company believes that its 1993 results will be much improved."
 Vital Heart Systems, Inc., with headquarters in Beverly, Mass., develops and markets the Variance Cardiograph, a non-invasive, stress- free, diagnostic instrument to aid physicians in the diagnosis of coronary artery disease. The stock of Vital Heart Systems, Inc., is traded on the over-the-counter market under the NASDAQ symbol VHRT.
 VITAL HEART SYSTEMS, INC.
 CONDENSED STATEMENT OF OPERATIONS
 Three Months Ended Year Ended
 12/31/92 12/31/91 12/31/92 12/31/91
 Revenues $110,721 $6,597 $374,144 $73,650
 Cost of sales
 & expenses (2,238,486) (158,012) (4,138,111) (1,742,593)
 Operating income
 (loss) (2,127,765) (151,415) (3,763,967) (1,668,943)
 Interest and misc.
 expenses (2,157) (93,253) (78,204) (59,650)
 Net income (loss) $(2,129,922) $(244,668) $(3,842,171)$(1,728,593)
 Net income (loss)
 per common share $(.10) $(.01) $(.19) $(.10)
 Weighted average
 shares 22,265,069 17,630,616 20,215,611 17,630,616
 -0- 4/20/93
 /CONTACT: Deborah Meacock, director, investor relations, Vital Heart Systems, 612-341-4489/
 (VHRT)


CO: Vital Heart Systems, Inc. ST: Minnesota, Massachusetts IN: MTC SU: ERN

KH -- MN006 -- 8158 04/20/93 14:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:568
Previous Article:NEWLY OPENED ARCO MINE WILL BE AUSTRALIA'S LARGEST UNDERGROUND COAL MINE WHEN FULLY OPERATIONAL NEXT YEAR
Next Article:SPICE UP MEXICAN AND SOUTHWEST FAVORITES WITH WESTERN MEXICAN DRESSING
Topics:


Related Articles
VITAL HEART SYSTEMS ANNOUNCES INCREASED REVENUES FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 1992
VITAL HEART SYSTEMS ANNOUNCES THIRD CONSECUTIVE QUARTER OF INCREASED REVENUES
VITAL HEART SYSTEMS ANNOUNCES THIRD QUARTER REVENUE ADJUSTMENT AND FOURTH QUARTER SALES
VITAL HEART SYSTEMS ANNOUNCES SECOND QUARTER AND SIX MONTH FINANCIALS
VITAL HEART SYSTEMS ANNOUNCES LICENSING AGREEMENT
ST. JUDE MEDICAL ANNOUNCES CHARGE FOR PURCHASED RESEARCH AND DEVELOPMENT COSTS
ST. JUDE MEDICAL REPORTS FOURTH QUARTER INCLUDING RESULTS FROM PACESETTER
ST. JUDE MEDICAL REPORTS PROFITS UP 24% FOR QUARTER AND YEAR
PLC SYSTEMS REPORTS FOURTH QUARTER AND YEAR END FINANCIAL RESULTS
PLC SYSTEMS Reports Third Quarter and Nine Month Financial Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters